LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

KemPharm Inc

Open

0

Overview

Share price change

24h

Current

Min

Max

Key metrics

By Trading Economics

Income

-2.5M

-36M

Sales

8.3M

12M

EPS

-0.69

Profit margin

-296.762

Employees

59

EBITDA

13M

-17M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+166.07% upside

Dividends

By Dow Jones

Next Earnings

12 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-7.5M

425M

Previous open

0

Previous close

0

KemPharm Inc Chart

Past performance is not a reliable indicator of future results.

Related News

27 Feb 2025, 15:29 UTC

Acquisitions, Mergers, Takeovers

Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million

5 Aug 2024, 11:25 UTC

Major Market Movers

Zevra Shares Rally Premarket After FDA Panel Backs Arimoclomol

Peer Comparison

Price change

KemPharm Inc Forecast

Price Target

By TipRanks

166.07% upside

12 Months Forecast

Average 22.43 USD  166.07%

High 25 USD

Low 19 USD

Based on 8 Wall Street analysts offering 12 month price targets forKemPharm Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

8

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$